PDF(Pubmed)
Abstract：
BACKGROUND: Cancer treatment-related cognitive impairment (CTRCI) can substantially reduce the quality of life of cancer survivors. Many treatments of CTRCI have been evaluated in randomized controlled trials (RCTs), including psychological interventions, pharmacologic interventions, and other therapies. There is a pressing need to establish the benefits and harms of previously studied CTRCI treatments. The proposed systematic review and network meta-analyses will assess the relative efficacy and safety of competing interventions for the management of CTRCI.
METHODS: In consultation with the review team, an experienced medical information specialist will draft electronic search strategies for MEDLINE®, Embase, CINAHL, PsycINFO, and the Cochrane Trials Registry. We will seek RCTs of interventions for the treatment of CTRCI in adults with any cancer, except cancers/metastases of the central nervous system. Due to the anticipated high search yields, dual independent screening of citations will be expedited by use of an artificial intelligence/machine learning tool. The co-primary outcomes of interest will be subjective and objective cognitive function. Secondary outcomes of interest will include measures of quality of life, mental and physical health symptoms, adherence to treatment, and harms (overall and treatment-related harms and harms associated with study withdrawal), where feasible, random-effects meta-analyses and network meta-analyses will be pursued. We will address the anticipated high clinical and methodological heterogeneity through meta-regressions, subgroup analyses, and/or sensitivity analyses.
CONCLUSIONS: The proposed systematic review will deliver a robust comparative evaluation of the efficacy and safety of existing therapies for the management of CTRCI. These findings will inform clinical decisions, identify evidence gaps, and identify promising therapies for future evaluation in RCTs.
METHODS: In consultation with the review team, an experienced medical information specialist will draft electronic search strategies for MEDLINE®, Embase, CINAHL, PsycINFO, and the Cochrane Trials Registry. We will seek RCTs of interventions for the treatment of CTRCI in adults with any cancer, except cancers/metastases of the central nervous system. Due to the anticipated high search yields, dual independent screening of citations will be expedited by use of an artificial intelligence/machine learning tool. The co-primary outcomes of interest will be subjective and objective cognitive function. Secondary outcomes of interest will include measures of quality of life, mental and physical health symptoms, adherence to treatment, and harms (overall and treatment-related harms and harms associated with study withdrawal), where feasible, random-effects meta-analyses and network meta-analyses will be pursued. We will address the anticipated high clinical and methodological heterogeneity through meta-regressions, subgroup analyses, and/or sensitivity analyses.
CONCLUSIONS: The proposed systematic review will deliver a robust comparative evaluation of the efficacy and safety of existing therapies for the management of CTRCI. These findings will inform clinical decisions, identify evidence gaps, and identify promising therapies for future evaluation in RCTs.
摘要：
背景：癌症治疗相关的认知障碍（CTRCI）可以大大降低癌症幸存者的生活质量。在随机对照试验（RCT）中已经评估了CTRCI的许多治疗方法，包括心理干预，药物干预，和其他疗法。迫切需要确定先前研究的CTRCI治疗的益处和危害。拟议的系统评价和网络荟萃分析将评估竞争干预措施对CTRCI管理的相对有效性和安全性。
方法：与审查小组协商后，一位经验丰富的医疗信息专家将为MEDLINE®起草电子搜索策略，Embase,CINAHL,PsycINFO,和Cochrane试验登记处.我们将寻求治疗任何癌症成人CTRCI的干预措施RCT，除了中枢神经系统的癌症/转移。由于预期的高搜索产量，通过使用人工智能/机器学习工具，将加快引用的双重独立筛选。感兴趣的共同主要结果将是主观和客观的认知功能。次要结果将包括生活质量的衡量，精神和身体健康的症状，坚持治疗，和危害（总体和治疗相关的危害以及与研究退出相关的危害），在可行的情况下，将进行随机效应荟萃分析和网络荟萃分析。我们将通过荟萃回归来解决预期的高临床和方法学异质性，亚组分析，和/或敏感性分析。
结论：拟议的系统评价将对现有治疗CTRCI的疗效和安全性进行有力的比较评估。这些发现将为临床决策提供信息，找出证据缺口，并确定有希望的治疗方法，用于RCT的未来评估。
方法：与审查小组协商后，一位经验丰富的医疗信息专家将为MEDLINE®起草电子搜索策略，Embase,CINAHL,PsycINFO,和Cochrane试验登记处.我们将寻求治疗任何癌症成人CTRCI的干预措施RCT，除了中枢神经系统的癌症/转移。由于预期的高搜索产量，通过使用人工智能/机器学习工具，将加快引用的双重独立筛选。感兴趣的共同主要结果将是主观和客观的认知功能。次要结果将包括生活质量的衡量，精神和身体健康的症状，坚持治疗，和危害（总体和治疗相关的危害以及与研究退出相关的危害），在可行的情况下，将进行随机效应荟萃分析和网络荟萃分析。我们将通过荟萃回归来解决预期的高临床和方法学异质性，亚组分析，和/或敏感性分析。
结论：拟议的系统评价将对现有治疗CTRCI的疗效和安全性进行有力的比较评估。这些发现将为临床决策提供信息，找出证据缺口，并确定有希望的治疗方法，用于RCT的未来评估。
